NYSE: CI · Healthcare Plans

Cigna (CI) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Cigna (CI) at $384.76 a share. The stock last closed at $300.16, which puts the model's fair value 28.2% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 16 Nov 2026. Cigna Corporation.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$384.76midpoint of 2,000 simulations
Last close$300.16NYSE: CI
Gap to fair value+28.2%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $380.49 to $384.76 (+1.1%). The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move.

What the model makes of itThe price of $300.16 is 28.2% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 8% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give CI?

The calibrated range for CI over 63 trading days is $273.43 to $331.05. It sits around the last close, and its width comes from the volatility that CI's own options imply (28% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $310.91 to $465.71. In 85% of the simulations the fair value came out above the price the model ran on.

$238.23$596.03
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $384.76. Dashed line: the last close, $300.16.

Faircurve Insights · 14 Nov 2026

Cigna Group is an insurer based in Bloomfield, Connecticut. Established in 1792, it provides insurance products and related services across the United States through two primary segments.

Faircurve's model gave a fair value of $384.76 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $380.49, so the fair value moved +1.1%. In the model's own words, the stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The calibrated range over 63 trading days is $273.43 to $331.05, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

On the model's quality scores, Cigna Group scores 68 out of 100 against comparable companies. Earnings quality is 87, with free cash flow to net income at 1.38x against a peer median of 0.44x. Stability is 85, with five-year EBITDA margin downside volatility at 0.7 pts against a peer median of 1.0 pts. Growth quality is 37, with trailing revenue growth at 11.3% against a peer median of 11.8%. The model compares Cigna with Elevance Health Inc. (ELV), Humana Inc. (HUM), CVS Health Corp. (CVS), Centene Corp. (CNC), UnitedHealth Group Incorporated (UNH), Molina Healthcare, Inc. (MOH) and Progyny, Inc. (PGNY).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does CI report earnings, and how has the stock reacted?

Cigna's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 3.8% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. CI's 30 day implied volatility works out to about 8.2% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CI's last 8 reports, ignoring direction, was 4.9%.

0%5%10%15%20%5.9%0.6%2 May '256.0%12.0%31 Jul '257.0%18.3%30 Oct '257.5%7.5%5 Feb '267.7%3.2%30 Apr '266.9%5.9%30 Jul '266.3%1.1%29 Oct '266.1%3.9%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in CI

0%5%10%15%5 Nov '26 report29 Oct '26 report30 Jul '26 report30 Apr '26 report5 Feb '26 report8% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 8% on 14 Nov 2025, reached 13% on 30 Jan 2026 and reads 8% on 16 Nov 2026. The marks are report dates.

How does CI score on business quality?

Cigna's overall quality score is 68 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.7411.3%ROIC10.1%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).871.38xFCF / net income0.44x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.3711.3%Revenue growth, trailing11.8%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.672.0%Net buybacks / market value1.5%
Balance sheetNet debt to EBITDA and interest coverage.581.99xNet debt / EBITDA2.40x
StabilityDownside volatility of the EBITDA margin over the last five years.850.7 ptsEBITDA margin downside volatility, 5y1.0 pts

How does CI compare with similar companies?

The companies in healthcare plans closest to Cigna in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
ELV Elevance Health Inc.$446.28$454.75+1.9%Fairly valued
HUM Humana Inc.$461.25$411.63-10.8%Fairly valued
CVS CVS Health Corp.$88.59$89.93+1.5%Fairly valued
CNC Centene Corp.$74.77$86.49+15.7%Undervalued
UNH UnitedHealth Group Incorporated$412.02$405.70-1.5%Fairly valued
MOH Molina Healthcare, Inc.$233.09$227.64-2.3%Fairly valued
PGNY Progyny, Inc.$37.15$34.78-6.4%Fairly valued

What the comparable companies' multiples alone would give for CI, the peer-implied price, is $644.03 a share on this run. The fair value weighs that against the company's own multiple.

All healthcare plan stocks ranked by gap to fair value

Cigna at a glance

Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments.

Market value
$78.3B
Sector
Healthcare
Industry
Healthcare Plans
Revenue expected, next twelve months
$298.2B
Consensus revenue growth, next fiscal year
+4.9%
Analysts with estimates
13
Beta to the US market
0.02
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CI was among them.

How the fair value is worked out: the model prices Cigna on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for CI was $380.49. As of 14 Nov 2026 it is $384.76, a change of +1.1%. The stock's own trading multiple rose with its price, and the fair value follows it in part: part of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Cigna's valuation

Is Cigna stock undervalued or overvalued?

On Faircurve's model, CI reads as Undervalued as of 14 Nov 2026. The model's fair value is $384.76 a share against a last close of $300.16, a gap of +28.2%.

What is CI's fair value?

$384.76 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $310.91 to $465.71.

What price range does the model give CI?

$273.43 to $331.05 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Cigna report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has CI moved on past earnings reports?

Across its last 8 reports the median two session move was 4.9%, ignoring direction. The largest was -18.3% around the report of 30 Oct 2025.

How confident is the model in this valuation?

The model's evidence grade for CI is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on CI

The model holds no idea open on CI today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CI with their outcomes. A free account is enough.

Keep reading